Filings under ALKS by Alnylam Pharmaceuticals, Inc. (CIK 0001178670) from Sep 11, 2013 to Dec 30, 2017 belong to a different issuer and are not shown. Filings under ALKS by Alkermes Inc (CIK 0000874663) from Jan 3, 2006 to Sep 16, 2011 belong to a different issuer and are not shown.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell(S) | 2K | $48.01 | $98K |
| Sep 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | — | $0 |
| Sep 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell(S) | 9K | $46.99 | $423K |
| Sep 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | $24.59 | $123K |
| Aug 17, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | Sell(S) | 664 | $49.65 | $33K |
| Aug 17, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | Sell(S) | 7K | $49.19 | $340K |
| Aug 5, 2026 | Jackson Blair Curtis | President & CEO, Alkermes plc, Director | Grant(A) | 124K | — | $0 |
| Aug 5, 2026 | Jackson Blair Curtis | President & CEO, Alkermes plc, Director | Grant(A) | 93K | — | $0 |
| Aug 3, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 104 | $19.34 | $2K |
| Aug 3, 2026 | snyderman nancy lynn MD | Director | Option exercise(M) | 28K | $46.72 | $1.3M |
| Aug 3, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 104 | — | $0 |
| Aug 3, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | $24.59 | $120K |
| Aug 3, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell(S) | 9K | $48.58 | $437K |
| Aug 3, 2026 | snyderman nancy lynn MD | Director | Option exercise(M) | 17K | $46.72 | $772K |
| Aug 3, 2026 | snyderman nancy lynn MD | Director | Option exercise(M) | 17K | — | $0 |
| Aug 3, 2026 | snyderman nancy lynn MD | Director | Option exercise(M) | 28K | — | $0 |
| Aug 3, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | — | $0 |
| Aug 3, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell(S) | 2K | $48.58 | $99K |
| Aug 3, 2026 | snyderman nancy lynn MD | Director | Sell(S) | 44K | $50.35 | $2.2M |
| Jul 6, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell(S) | 2K | $54.03 | $110K |
| Jul 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell(S) | 700 | $52.13 | $36K |
| Jul 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell(S) | 8K | $51.46 | $427K |
| Jul 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | $19.34 | $97K |
| Jul 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | — | $0 |
| Jun 12, 2026 | Wright Christopher I | Director | Sell(S) | 2K | $45.10 | $90K |
| Jun 4, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell(S) | 2K | $43.05 | $88K |
| Jun 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | — | $0 |
| Jun 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell(S) | 9K | $41.67 | $375K |
| Jun 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | $19.34 | $97K |
| May 29, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Option exercise(M) | 13K | — | $0 |
| May 29, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Option exercise(M) | 3K | $20.03 | $68K |
| May 29, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Sell(S) | 16K | $42.36 | $687K |
| May 29, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Option exercise(M) | 3K | — | $0 |
| May 29, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Option exercise(M) | 13K | $19.34 | $248K |
| May 21, 2026 | McKeon Brian P | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | Wright Christopher I | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | Wright Christopher I | Director | Tax withholding(F) | 1K | $36.95 | $55K |
| May 21, 2026 | McKeon Brian P | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | Lurker Nancy | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | McKeon Brian P | Director | Tax withholding(F) | 1K | $36.95 | $55K |
| May 21, 2026 | snyderman nancy lynn MD | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | Wilson Frank Anders | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | Wilson Frank Anders | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | Wright Christopher I | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | Lurker Nancy | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | Wilson Frank Anders | Director | Tax withholding(F) | 1K | $36.95 | $55K |
| May 21, 2026 | Laurencin Cato T | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | Lurker Nancy | Director | Tax withholding(F) | 1K | $36.95 | $55K |
| May 21, 2026 | snyderman nancy lynn MD | Director | Option exercise(M) | 6K | — | — |
| May 21, 2026 | snyderman nancy lynn MD | Director | Tax withholding(F) | 1K | $36.95 | $55K |
| May 21, 2026 | Laurencin Cato T | Director | Tax withholding(F) | 1K | $36.95 | $55K |
| May 21, 2026 | Laurencin Cato T | Director | Option exercise(M) | 6K | — | — |
| May 20, 2026 | Wright Christopher I | Director | Grant(A) | 5K | — | $0 |
| May 20, 2026 | McKeon Brian P | Director | Grant(A) | 5K | — | $0 |
| May 20, 2026 | Wright Christopher I | Director | Grant(A) | 12K | — | $0 |
| May 20, 2026 | Gaynor Richard | Director | Grant(A) | 5K | — | $0 |
| May 20, 2026 | McKeon Brian P | Director | Grant(A) | 12K | — | $0 |
| May 20, 2026 | Lurker Nancy | Director | Grant(A) | 12K | — | $0 |
| May 20, 2026 | Wilson Frank Anders | Director | Grant(A) | 12K | — | $0 |
| May 20, 2026 | Laurencin Cato T | Director | Grant(A) | 12K | — | $0 |
| May 20, 2026 | snyderman nancy lynn MD | Director | Grant(A) | 12K | — | $0 |
| May 20, 2026 | Gaynor Richard | Director | Grant(A) | 12K | — | $0 |
| May 20, 2026 | Laurencin Cato T | Director | Grant(A) | 5K | — | $0 |
| May 20, 2026 | Cooke Shane | Director | Grant(A) | 5K | — | $0 |
| May 20, 2026 | snyderman nancy lynn MD | Director | Grant(A) | 5K | — | $0 |
| May 20, 2026 | Wilson Frank Anders | Director | Grant(A) | 5K | — | $0 |
| May 20, 2026 | Lurker Nancy | Director | Grant(A) | 5K | — | $0 |
| May 20, 2026 | Cooke Shane | Director | Grant(A) | 12K | — | $0 |
| May 4, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell(S) | 2K | $33.20 | $68K |
| May 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | $19.34 | $97K |
| May 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell(S) | 9K | $33.40 | $301K |
| May 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | — | $0 |
| Apr 11, 2026 | Lurker Nancy | Director | Option exercise(M) | 4K | — | — |
| Apr 11, 2026 | Lurker Nancy | Director | Tax withholding(F) | 901 | $33.36 | $30K |
| Apr 11, 2026 | Lurker Nancy | Director | Option exercise(M) | 4K | — | — |
| Apr 6, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell(S) | 2K | $34.57 | $70K |
| Apr 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell(S) | 9K | $35.51 | $320K |
| Apr 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | $19.34 | $97K |
| Apr 1, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | — | $0 |
| Mar 3, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell(S) | 2K | $29.76 | $61K |
| Mar 2, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Grant(A) | 14K | — | $0 |
| Mar 2, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Grant(A) | 15K | — | $0 |
| Mar 2, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Sell(S) | 7K | $29.29 | $202K |
| Mar 2, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | Grant(A) | 31K | — | $0 |
| Mar 2, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | Grant(A) | 66K | — | $0 |
| Mar 2, 2026 | Reed Joshua | SVP, Chief Financial Officer | Grant(A) | 31K | — | $0 |
| Mar 2, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | Grant(A) | 95K | — | $0 |
| Mar 2, 2026 | Jackson Blair Curtis | EVP, Chief Operating Officer | Grant(A) | 44K | — | $0 |
| Mar 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Grant(A) | 83K | — | $0 |
| Mar 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Grant(A) | 39K | — | $0 |
| Mar 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | — | $0 |
| Mar 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise(M) | 5K | $19.34 | $97K |
| Mar 2, 2026 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell(S) | 9K | $29.72 | $267K |
| Mar 2, 2026 | Nichols Christian Todd | SVP, Chief Commercial Officer | Sell(S) | 6K | $30.00 | $180K |
| Mar 2, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Grant(A) | 78K | — | $0 |
| Mar 2, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Grant(A) | 36K | — | $0 |
| Mar 2, 2026 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell(S) | 2K | $29.29 | $60K |
| Mar 2, 2026 | Pops Richard F | Director and CEO, Alkermes plc, Director | Grant(A) | 89K | — | $0 |
| Mar 2, 2026 | Reed Joshua | SVP, Chief Financial Officer | Grant(A) | 66K | — | $0 |
| Feb 26, 2026 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Option exercise(M) | 3K | — | — |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Alkermes plc., SEC CIK 0001520262. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under ALKS and shows every filing by that issuer. Earlier filings under the same symbol by another issuer are left out.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-19. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for ALKS